ClinicalTrials.gg
RecruitingNCT04869098PROPENSITyUpdated Dec 24, 2024

Effects of an Evening PROtein PrEload on Metabolic Health in Night ShIfT Workers (PROPENSITy)

An interventional study of whey protein and Placebo in Type 2 Diabetes and Shift-work Disorder, sponsored by University of Adelaide. Recruiting at 1 site in Australia. Open to female participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-24.

Sponsored by University of Adelaide · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Apr 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 262 studies in Diabetes Mellitus, Type 2 with a site in Australia — 24 open to participants now, 30 under way, 13 of them phase 3. Diabetes Mellitus, Type 2 · Australia.

Planned enrollment
228th of 246
30 · median 392
Started
2021
with 5 others
No phase
31 of 262
4 open now
Primary completion
2025-07
later than 1 of 29 live
Registered
211th of 262
by date

Among the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia, this one is the 228th largest by planned enrollment of the 246 interventional ones that give a count, is one of 6 that started in 2021, is one of 31 with no phase, reaches primary completion later than 1 of the 29 other live ones, and was the 211th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

24 of the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 35 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Diabetes Mellitus, Type 2 with a site in Australia, or all of them as a file.
02

Study summary

This study will compare the effects of a whey protein supplement or a placebo consumed before the evening meal on health outcomes in night shift workers.

Read the detailed description

Participants are assigned in random order to two conditions, for 12 days each. The interventions are 1) a 30g whey protein preload consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given. 2) an identical mixed-nutrient drink matched for caloric content, taste and palatability consumed 1-1.5 hr prior to their main evening meal every day for 12 days(placebo). Conditions are separated by a 2-week washout period, during which participants will be encouraged to maintain their habitual diet and physical activity levels. Metabolic testing will be performed at baseline, and at the end of both conditions.

03

Conditions studied

  • Type 2 Diabetes
  • Shift-work Disorder
04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • Night shift workers (with a minimum of 6 months in their current shift work schedule)
  • 35-65 years
  • 28.0-35.0 kg/m2; waist circumference > 80cm
  • Weight stable in the past 6 months

Exclusion criteria

Exclusion Criteria:

  • Those working standard day time hours only, or those who work less than three to four night shifts per fortnight on average
  • Personal history and/or diagnosis of: diabetes, cancer, major psychiatric disorders, liver disease, gastro-intestinal surgery or disease (including malabsorption), eating disorders, anaemia, insomnia or cardiovascular disease, and/or any other condition deemed unstable by the study physician
  • Taking medications known to alter body composition or metabolism, including (but not limited to): any medication used to lower blood glucose or antidiabetic medications (metformin, sulfonylureas, Glucagon-like peptide-1 (GLP-1) analogues [i.e. exenatide], thiazolidinediones or DPP-IV inhibitors [i.e. 'gliptins']), medications affecting weight, appetite or gut motility (i.e. diuretics, domperidone, cisapride, orlistat, phentermine, topiramate)
  • Participants who are taking stable doses (i.e. > 12 months) of androgenic medications (i.e. testosterone) or SSRI's will not be excluded. Personal history/diagnosis (self-reported) of diabetes (type 1 or 2), major psychiatric disorders (schizophrenia, major depressive disorder, bipolar disorder, eating disorders), gastrointestinal disorders, haematological disorders (i.e. thalassemia, iron-deficiency anaemia) insomnia, or any other medical condition, deemed unstable by the study physician
  • Pregnant, planning a pregnancy or breastfeeding
  • Those who have lost or gained >5% of body weight in the last 6 months
  • Those who consume four or more standard drinks on a single occasion at a 'daily or almost daily' occurrence
  • current smokers of cigarettes/marijuana/e-cigarettes/vaporisers
  • unable to comprehend the study protocol (i.e. due to English language or cognitive difficulties)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Whey protein preload condition

    Participants will consume 30 g whey protein isolate powder (dissolved in water) 1-1.5 hr prior to their main evening meal every day for 12 days.

    Dietary Supplement: whey protein

  • Placebo comparator
    Placebo condition

    Participants will consume an energy-matched mixed-nutrient placebo drink 1-1.5 hr prior to their main evening meal every day for 12 days,

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementWhey ProteinsStudies of Whey ProteinsWhey Proteins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.

  • Dietary supplementPlacebo

    Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.

06

What researchers measure

Primary outcomes

  1. Glycaemic response

    Change in glucose (AUC) following a standard breakfast

    Time frame: 12 days (3 hours meal test)

Secondary outcomes

  1. 24-hour glucose profiles

    Change in 24-hour glucose profiles assessed by continuous glucose monitoring

    Time frame: 12 days

  2. Glucose variability

    Change in 24-hour glucose variability (as SD, standard deviation) assessed by continuous glucose monitoring

    Time frame: 12 days

  3. Glucose variability

    Change in 24-hour glucose variability (as CV, coefficients of variation) assessed by continuous glucose monitoring

    Time frame: 12 days

  4. Glucose variability

    Change in 24-hour glucose variability (as MAGE, mean amplitude of gylcaemic excursions) assessed by continuous glucose monitoring

    Time frame: 12 days

  5. GLP-1

    Change in GLP-1 (AUC) following a standard breakfast

    Time frame: 12 days (3 hours meal test)

  6. GIP

    Change in GIP (AUC) following a standard breakfast

    Time frame: 12 days (3 hours meal test)

  7. glucagon

    Change in glucagon (AUC) following a standard breakfast

    Time frame: 12 days (3 hours meal test)

  8. Insulin

    Change in fasting and postprandial insulin following a standard breakfast

    Time frame: 12 days

  9. Ghrelin

    Change in ghrelin (AUC) following a standard breakfast

    Time frame: 12 days (3 hours meal test)

  10. PYY

    Change in YY (AUC) following a standard breakfast

    Time frame: 12 days

  11. Adiponectin

    Change in fasting adiponectin

    Time frame: 12 days

  12. C-Reactive Protein (CRP)

    Change in fasting CRP

    Time frame: 12 days

  13. Blood lipids

    Changes in blood lipid profile (total cholesterol, HDL-, LDL-cholesterol and triglycerides)

    Time frame: 12 days

  14. Blood pressure

    Changes in systolic blood pressure and diastolic blood pressure

    Time frame: 12 days

  15. Resting metabolic rate

    Changes in resting metabolic rate

    Time frame: 12 days

  16. respiratory quotient

    Changes in respiratory quotient

    Time frame: 12 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Jul 2025, 51 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 51 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2021
First posted
May 3, 2021
StartActual
Apr 27, 2021
Primary completionEst.
Jul 31, 2025
CompletionEst.
Jul 31, 2026
Last update
Dec 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04869098
Lead sponsor
University of Adelaide
Responsible party
A/Prof Leonie Heilbronn (A/Prof, University of Adelaide) — Principal investigator
First posted
May 3, 2021
Start date
Apr 27, 2021
Primary completion
Jul 31, 2025 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Dec 24, 2024

Study contacts

Amy Hutchison, PhD
Contact
amy.hutchison@adelaide.edu.au
8128 4862
Leonie Heilbronn, PhD
Contact
leonie.heilbronn@adelaide.edu.au
8128 4838
Amy T Hutchison, PhD
principal investigator · University of Adelaide

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Whey Proteins

Start the discussion